Skip to main content
Top
Published in:

Open Access 02-07-2024 | Pseudomonas Aeruginosa | Review

Impact of multidrug resistance on the virulence and fitness of Pseudomonas aeruginosa: a microbiological and clinical perspective

Authors: Elena Sendra, Almudena Fernández-Muñoz, Laura Zamorano, Antonio Oliver, Juan Pablo Horcajada, Carlos Juan, Silvia Gómez-Zorrilla

Published in: Infection | Issue 4/2024

Login to get access

Abstract

Pseudomonas aeruginosa is one of the most common nosocomial pathogens and part of the top emergent species associated with antimicrobial resistance that has become one of the greatest threat to public health in the twenty-first century. This bacterium is provided with a wide set of virulence factors that contribute to pathogenesis in acute and chronic infections. This review aims to summarize the impact of multidrug resistance on the virulence and fitness of P. aeruginosa. Although it is generally assumed that acquisition of resistant determinants is associated with a fitness cost, several studies support that resistance mutations may not be associated with a decrease in virulence and/or that certain compensatory mutations may allow multidrug resistance strains to recover their initial fitness. We discuss the interplay between resistance profiles and virulence from a microbiological perspective but also the clinical consequences in outcomes and the economic impact.
Literature
This content is only visible if you are logged in and have the appropriate permissions.
Metadata
Title
Impact of multidrug resistance on the virulence and fitness of Pseudomonas aeruginosa: a microbiological and clinical perspective
Authors
Elena Sendra
Almudena Fernández-Muñoz
Laura Zamorano
Antonio Oliver
Juan Pablo Horcajada
Carlos Juan
Silvia Gómez-Zorrilla
Publication date
02-07-2024
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 4/2024
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-024-02313-x

Innovations in AML: insights and practical guidance

Hear directly from acute myeloid leukemia experts in this vodcast series focussing on innovations in molecular testing, emerging therapies, and targeted treatments, and get practical advice for improving the care of your patients with relapsed or refractory disease.

Supported by:
  • Rigel Pharmaceuticals, Inc.
Developed by: Springer Health+ IME
Learn more

ADA 2025

Unlock your free and exclusive access to the latest news from the American Diabetes Association’s 85th Scientific Sessions.

Read more